Document Detail

Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.
MedLine Citation:
PMID:  16908351     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Rituximab is an anti-CD20 chimeric antibody that selectively targets B lymphocytes. Recently, it has been reported to be beneficial in treating pemphigus vulgaris. OBJECTIVE: Our aim was to review the English-language literature on the treatment of pemphigus vulgaris (PV) with rituximab and to determine its efficacy and influence on clinical outcome(s). MATERIAL AND METHODS: A retrospective review of the literature on the use of rituximab in the treatment of PV was conducted. Seventeen patients in 10 reports were described and their data were reviewed. RESULTS: The majority of patients received one course of rituximab along with conventional immunosuppressive therapy as concomitant therapy; 88% of the patients demonstrated improvement. More than half of the patients were followed up for more than 6 months after rituximab treatment; they appeared to be clinically disease free, but were still receiving conventional immunosuppressive therapy. Side effects in most patients were transient and infusion related. Serious infections occurred in 4 patients. One patient died. LIMITATIONS: The sample size of this study is small; there is no uniformity of data collection or measurement of key and critical indices, and follow-up was limited. CONCLUSION: Rituximab may be a promising agent in treatment of PV.
Abdul Kader El Tal; Marshall R Posner; Zachary Spigelman; A Razzaque Ahmed
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of the American Academy of Dermatology     Volume:  55     ISSN:  1097-6787     ISO Abbreviation:  J. Am. Acad. Dermatol.     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-08-15     Completed Date:  2006-09-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7907132     Medline TA:  J Am Acad Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  449-59     Citation Subset:  IM    
Department of Medicine, New England Baptist Hospital, Harvard School of Dental Medicine, Boston, Massachusetts 02120, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies / blood
Antibodies, Monoclonal / immunology,  therapeutic use*
Antigens, CD20 / immunology*
B-Lymphocytes / pathology
Immunologic Factors / therapeutic use*
Lymphocyte Count
Pemphigus / drug therapy*,  immunology
Reg. No./Substance:
0/Antibodies; 0/Antibodies, Monoclonal; 0/Antigens, CD20; 0/Immunologic Factors; 0/rituximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A risk management program aimed at preventing fetal exposure to isotretinoin: retrospective cohort s...
Next Document:  Is melanocytic nevus with focal atypical epithelioid components (clonal nevus) a superficial variant...